Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin 300052, China.
Laboratory of Neuro-Oncology, Tianjin Neurological Institute, Tianjin 300052, China.
Cells. 2022 Aug 17;11(16):2556. doi: 10.3390/cells11162556.
Heat-shock protein 90 (HSP90) is an important molecule chaperone associated with tumorigenesis and malignancy. HSP90 is involved in the folding and maturation of a wide range of oncogenic clients, including diverse kinases, transcription factors and oncogenic fusion proteins. Therefore, it could be argued that HSP90 facilitates the malignant behaviors of cancer cells, such as uncontrolled proliferation, chemo/radiotherapy resistance and immune evasion. The extensive associations between HSP90 and tumorigenesis indicate substantial therapeutic potential, and many HSP90 inhibitors have been developed. However, due to HSP90 inhibitor toxicity and limited efficiency, none have been approved for clinical use as single agents. Recent results suggest that combining HSP90 inhibitors with other anticancer therapies might be a more advisable strategy. This review illustrates the role of HSP90 in cancer biology and discusses the therapeutic value of Hsp90 inhibitors as complements to current anticancer therapies.
热休克蛋白 90（HSP90）是一种与肿瘤发生和恶性肿瘤相关的重要分子伴侣。HSP90 参与多种致癌客户的折叠和成熟，包括各种激酶、转录因子和致癌融合蛋白。因此，可以说 HSP90 促进了癌细胞的恶性行为，如不受控制的增殖、化疗/放疗耐药和免疫逃避。HSP90 与肿瘤发生之间的广泛关联表明其具有很大的治疗潜力，并且已经开发了许多 HSP90 抑制剂。然而，由于 HSP90 抑制剂的毒性和有限的效率，没有一种被批准作为单一药物用于临床。最近的结果表明，将 HSP90 抑制剂与其他抗癌疗法联合使用可能是一种更明智的策略。本文综述了 HSP90 在癌症生物学中的作用，并讨论了 Hsp90 抑制剂作为现有抗癌疗法的补充的治疗价值。
